background
respiratori
tract
infect
common
caus
hospit
infant
young
children
typic
caus
viral
less
commonli
bacteri
pathogen
exist
nonmolecular
diagnost
method
sever
drawback
limit
sensit
long
turnaround
time
limit
number
pathogen
detect
object
nucleic
acid
amplif
method
increas
sensit
enabl
initi
appropri
intervent
without
delay
broadspectrum
detect
identif
circumv
use
individu
diagnost
dna
rna
base
assay
present
sever
commerci
assay
avail
broadspectrum
detect
studi
design
compar
perform
xtag
respiratori
viral
panel
rvp
luminex
molecular
diagnost
toronto
canada
respifind
pathofind
maastricht
netherland
extern
qualiti
assur
eqa
panel
qcmd
scotland
consist
total
eqa
sampl
result
rvp
respifind
assay
excel
specif
sensit
rvp
respifind
assay
respect
assay
sensit
low
weak
posit
sampl
discuss
result
studi
seem
indic
better
sensit
respifind
analysi
patient
sampl
necessari
evalu
clinic
perform
lower
respiratori
tract
infect
lrti
common
caus
hospit
caus
variou
bacteri
viral
pathogen
date
virus
shown
caus
respiratori
tract
infect
everi
year
new
virus
associ
lrti
studi
suggest
earli
accur
identif
viral
etiolog
agent
emerg
depart
evalu
hospit
patient
associ
decreas
antibiot
use
decreas
number
addit
test
perform
decreas
length
stay
emerg
depart
decreas
length
hospit
stay
clinic
diagnosi
respiratori
tract
infect
difficult
patient
atyp
ill
characterist
low
preval
set
identif
etiolog
agent
use
need
specif
therapeut
approach
hospit
hygien
measur
necessari
epidemiolog
reason
laboratori
techniqu
antigen
immunoassay
viral
cultur
serolog
sever
shortcom
limit
sensit
long
turnaround
time
limit
spectrum
detect
pathogen
combin
method
often
necessari
improv
diagnosi
use
nucleic
acid
amplif
test
naat
polymeras
chain
reaction
pcr
enabl
day
detect
causal
pathogen
therefor
prompt
initi
appropri
intervent
multi
paramet
naat
allow
broad
spectrum
detect
pathogen
therebi
save
time
work
addit
studi
brunstein
colleagu
report
preliminari
clinic
evid
diagnosi
coinfect
medic
relev
effect
treatment
sever
rti
requir
detect
involv
pathogen
studi
compar
perform
xtag
respiratori
viral
panel
rvp
assay
luminex
molecular
diagnost
toronto
canada
respifind
assay
respifind
pathofind
maastricht
netherland
detect
viral
respiratori
pathogen
rvp
assay
compris
multiplex
revers
transcript
polymeras
chain
reaction
rtpcr
follow
multiplex
targetspecif
primer
extens
targetspecif
primer
see
front
matter
elsevi
bv
right
reserv
chimer
primer
juxtapos
univers
tag
sequenc
allow
sort
luminex
xmap
instrument
respifind
assay
base
multiplex
ligationdepend
probe
amplif
mlpa
technolog
mlpa
reaction
preced
preamplif
step
ensur
detect
dna
rna
virus
specif
sensit
individu
singleplex
realtim
rtpcr
assay
detect
differenti
follow
respiratori
virus
influenza
infa
b
infb
respiratori
syncyti
viru
rsva
b
rsvb
parainfluenza
coronaviru
coronaviru
coronaviru
human
metapneumoviru
hmpv
adenoviru
adeno
addit
assay
probe
infa
includ
rvp
assay
also
subtyp
infa
infa
respifind
assay
detect
rhinoviru
rhino
also
detect
rvp
assay
differenti
rhinoviru
enteroviru
rhinoentero
moreov
detect
coronaviru
coronaviru
sar
sarscov
also
includ
rvp
assay
total
extern
qualiti
assur
eqa
panel
qcmd
scotland
contain
eqa
sampl
sampl
expect
posit
influenza
respiratori
syncyti
viru
parainfluenza
coronaviru
rhinoviru
human
metapneumoviru
adenoviru
analyz
extract
nucleic
acid
na
perform
easymag
lyon
franc
use
gener
protocol
extract
amplif
control
includ
everi
sampl
accord
manufactur
instruct
sampl
volum
extract
l
elut
volum
l
rvp
l
respifind
panel
analyz
rvp
respifind
assay
accord
manufactur
instruct
respect
l
rvp
l
respifind
na
ad
pcr
mixtur
result
end
concentr
total
sampl
concentr
assay
amplif
hybrid
ligat
perform
biorad
laboratori
hercul
ca
us
rvp
data
acquisit
perform
luminex
molecular
diagnost
use
tda
softwar
respifind
fragment
analysi
perform
ceq
genet
analysi
system
beckman
coulter
brea
ca
us
follow
analysi
fragment
analysi
softwar
neg
sampl
neg
result
obtain
assay
posit
result
found
respifind
assay
posit
sampl
fals
neg
sampl
weak
posit
except
adenoviru
type
sampl
weak
posit
sampl
inconclus
result
extract
amplif
control
neg
obtain
weak
posit
sampl
sampl
stock
dilut
ctvalu
independ
test
concentr
copiesml
sampl
neg
inconclus
result
obtain
sampl
expect
ctvalu
addit
adenoviru
detect
rsv
posit
sampl
confirm
adenoviru
specif
realtim
pcr
infa
sampl
variant
also
detect
rvp
posit
sampl
adenoviru
sampl
fals
neg
furthermor
sampl
fals
neg
sensit
weak
posit
sampl
respifind
rvp
result
shown
tabl
supplementari
data
tabl
assay
excel
specif
demonstr
concord
result
neg
sampl
rvp
posit
sampl
result
overal
sensit
limit
sensit
explain
limit
sensit
adenoviru
infa
weak
posit
sampl
posit
result
found
respifind
assay
sampl
equival
overal
sensit
gener
fals
neg
result
explain
limit
sensit
weak
posit
sampl
fals
posit
result
infa
could
probabl
explain
crosshybrid
variant
infa
probe
accord
kit
insert
diagnosi
infect
may
base
posit
find
respifind
assay
alon
weak
posit
sampl
sensit
low
assay
notic
less
particip
eqa
round
report
posit
result
weak
posit
sampl
furthermor
clinic
relev
weak
posit
sampl
remain
unclear
recent
studi
publish
utokaparch
et
al
suggest
total
viral
load
children
lrti
significantli
increas
compar
children
nonlrti
studi
perform
qualiti
assur
sampl
obtain
result
confirm
analysi
clinic
sampl
howev
analyt
evalu
result
give
indic
technic
perform
assay
studi
clinic
perform
rvp
mahoni
et
al
seem
indic
rvp
higher
sensit
compar
direct
fluorescentantibodi
assay
dfa
cultur
sensit
respifind
compar
cell
cultur
except
data
perform
characterist
commerci
multiplex
assay
show
assay
sensit
viral
cultur
studi
compar
perform
commerci
avail
multiplex
assay
studi
baladallasat
et
al
evalu
perform
commerci
assay
diagnosi
respiratori
viral
infect
adult
show
compar
cultur
rvp
sensit
specif
compar
multicodeplx
eragen
bioscienc
madison
wi
us
resplex
ii
qiagen
hilden
germani
respect
howev
resplex
ii
offer
broadest
viru
detect
rang
multicodeplx
offer
greater
eas
use
anoth
studi
seem
indic
respifind
better
sensit
seeplex
detect
kit
seegen
rockvil
md
us
conclud
multi
paramet
assay
use
tool
broad
spectrum
detect
respiratori
pathogen
although
timeto
result
could
improv
neg
result
interpret
care
limit
sensit
pathogen
fund
none
compet
interest
none
declar
ethic
approv
requir
